Allergan announced the launch of paliperidone extended-release tablets, the generic version of Janssen’s Invega. This is the first generic launch of Invega in the U. S.
Invega is an atypical antipsychotic indicated for acute and maintenance treatment of schizophrenia in adults; acute treatment of schizoaffective disorder in adults, as monotherapy or as an adjunct to mood stabilizer and/or antidepressants, and for treatment of schizophrenia in adolescents 12–17 years of age.
Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of D2 and 5HT2A receptor antagonism.
Paliperidone is available as 1.5mg, 3mg, 6mg, and 9mg strength extended-release tablets.
For more information, visit Invega.com.
This article originally appeared on MPR